The L-dopa sparing effect of G 31,406 in the treatment of parkinson's disease.
The AA. study 60 cases of Parkinsonism treated with levodopa associated to G31,406 (dibenzazepnic derivative), to amantadine and to a placebo. Drug-associations: 1) L-dopa + G 31.406, of anticataleptic effect, probably because of its anticholinergic activity and adrenergic central and/or dopaminergic stimulating action; 2) L-Dopa + chl. amantadine; 3) L-dopa + placebo. The patients were previously under exclusive use of L-dopa. The assay verifies: a) if there is any benefit with these associations and in what proportions; b) incidence and intensity of side effects; c) comparative study. The assay also intends to evaluate the effect of the G 31.406 on the depression which usually occur in Parkinsonians.
D000547:Amantadine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy; D003984:Dibenzazepines / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D010919:Placebos
D003984:Dibenzazepines; D010919:Placebos; D007980:Levodopa; D000547:Amantadine